Peptide therapy, decoded.

200+ clinical monographs, interactive dosing calculators, and community reviews — all PubMed-referenced and free to access.

200+ Monographs·14 Clinical Tools·37 Languages·PubMed-Referenced·No Pharmacy Affiliations

Latest Research & Education

Article

Peptide Angio-3 Attenuates Pulmonary Fibrosis Via Modulation of Coagulation Factor Xa-PAR-1 Signaling Axis

Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, demonstrated significant antifibrotic activity in pulmonary fibrosis models by functioning as a PAR-1 antagonist that disrupts the coagulation factor Xa-PAR-1 signaling axis. The peptide inhibited fibroblast invasion and migration with a favorable safety profile—no adverse effects at 0.5 mg/kg/day and only mild hepatomegaly at supratherapeutic doses.

Peptide Publicus Editorial··1 min read
Evidence-based
Guides

Guide complet de la thérapie peptidique 2026

La thérapie peptidique en 2026 : mécanismes d'action, peptides approuvés par l'EMA et l'ANSM, applications cliniques validées, cadre réglementaire francophone et perspectives. Un guide complet pour comprendre cette classe thérapeutique en pleine expansion.

Peptide Publicus Editorial··10 min read
Evidence-based
Review

Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review

A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, finding selective cytotoxicity against tumor cells via membrane disruption and apoptosis induction, though clinical evidence remains limited to early-phase trials.

Peptide Publicus Editorial··2 min read
Evidence-based
Article

Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial

The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing significant MASH resolution without worsening fibrosis at 24 weeks. FDA granted Breakthrough Therapy designation in January 2026.

Peptide Publicus Editorial··2 min read
Evidence-based
Article

Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial

Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight reduction at 68 weeks in the pivotal TRIUMPH-4 trial — the largest weight loss ever reported for any anti-obesity medication in Phase 3.

Peptide Publicus Editorial··2 min read
Evidence-based
Informational

Les peptides sont-ils sûrs ? Ce que montre la recherche clinique

Les peptides thérapeutiques suscitent un intérêt croissant, mais sont-ils réellement sûrs ? Cet article passe en revue les données cliniques, les cadres réglementaires (ANSM, EMA, Swissmedic) et les profils de tolérance pour vous aider à comprendre ce que la science dit vraiment sur la sécurité des peptides.

Peptide Publicus Editorial··7 min read
Evidence-based

Real Experiences from Real UsersNEW

BPC-157
Worth it

Game-changer for my knee recovery

After 6 weeks of subcutaneous injections, the chronic tendon pain I'd had for 2 years was down to almost nothing. Combined with PT, the results were remarkable.

Verified user · 8 weeks

Semaglutide
Worth it

Steady weight loss, minimal sides

Lost 14 lbs over 3 months on the titration schedule. Nausea was real the first 2 weeks but manageable. Worth it for the appetite control alone.

Verified user · 12 weeks

CJC-1295 + Ipamorelin
Worth it

Best GH stack I've tried

Noticeably better sleep by week 2, improved recovery from training by week 4. Skin quality improved. No water retention like with GHRP-6.

Verified user · 16 weeks

200+

Monographs

14

Interactive Tools

37

Languages

100%

Independent

Restez en Avance

Mises à jour cliniques, actualités du secteur, nouvelles synthèses de recherche et lancements d'outils.

Nous respectons votre vie privée. Désabonnez-vous à tout moment.